Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,430.92
(
-0.94%
)
US TECH 100
28,417.90
(
-1.30%
)
Dow Jones
49,726.94
(
-0.67%
)
Brent Oil
106.29
(
2.02%
)
Bitcoin
79,061.96
(
-2.46%
)
News Focus
News Focus
Post# of 257570
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122985
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 106479

Thursday, 10/20/2011 2:16:52 AM

Thursday, October 20, 2011 2:16:52 AM

Post# of 257570
SNY reports additional Aubagio (f/k/a teriflunomide) data from phase-3 TEMSO study in RRMS and reveals that the NDA has been accepted by the FDA for review:

http://finance.yahoo.com/news/Oral-Therapy-Teriflunomide-prnews-1797152570.html?x=0&.v=4

Assuming a standard review (the PR would presumably have said so if a priority review), the PDUFA date is in June 2012. The PR above says SNY intends to submit a European MAA in 1Q12, which could allow EU approval in 1H13.

Aubagio is one of the various oral threats to Copaxone, so it bears watching for MNTA and TEVA investors.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today